Showing results (801-810 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|December 14, 2020
Treatment of HF in an Era of Multiple Therapies: Statement From the HF CollaboratoryAnkeet S Bhatt, William T Abraham, JoAnn Lindenfeld, et al.
Nature Medicine|October 6, 2025
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fractionMuthiah Vaduganathan, Brian L Claggett, Safia Chatur, et al.
Journal of the American College of Cardiology|November 6, 2024
Artificial Intelligence in Cardiovascular Clinical TrialsJonathan W Cunningham, William T Abraham, Ankeet S Bhatt, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
European Heart Journal|June 18, 2015
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)Stefan D Anker, Andrew J S Coats, Gabriel Cristian, et al.
European Journal of Heart Failure|December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HFUlrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart FailureMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
Pageof 122